

Supplement Documents [IFRS]

Financial results for the first six months of the fiscal year 2015 (FY2015)

ending March 31, 2016.

Astellas Pharma Inc.

- Financial Results of 2Q/FY2015
 - Six months ended September 30, 2015
 - Three months ended September 30, 2015
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

[Six months ended September 30, 2015]

1. Consolidated Results (Full Basis)

	billion yen				FY14 Full Year	Initial Forecasts		Revised Forecasts		Change from FY14 Change (%)
	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)		FY15 Full Year	FY15 Full Year	Change (%)		
Sales	594.5	687.5	93.0	15.7%	1,247.3	1,362.0	1,384.0	11.0%		
Cost of sales	159.1	168.4	9.3	5.8%	333.2					
Ratio to Sales	26.8%	24.5%			26.7%					
Gross profit	435.4	519.1	83.7	19.2%	914.1					
SG&A expenses	201.8	239.7	38.0	18.8%	452.5					
Ratio to Sales	33.9%	34.9%			36.3%					
Advertising and Sales Promotion	55.0	83.3	28.3	51.4%	138.5					
Personnel expenses	85.3	91.3	6.0	7.0%	178.1					
Other	61.4	65.1	3.7	6.0%	136.0					
R&D expenses	97.0	112.0	15.0	15.5%	206.6	229.0	238.0	15.2%		
Ratio to Sales	16.3%	16.3%			16.6%	16.8%	17.2%			
Amortisation of intangible assets	17.9	21.9	4.0	22.1%	38.7					
Share of profits/losses of associates and joint ventures	0.5	-0.3	-0.8	-	0.2					
Other income	4.9	0.9	-4.0	-81.7%	12.5					
Gain on sales of property, plant and equipment	1.4	0.2	-1.2	-82.5%	1.4					
Net foreign exchange gains	1.7	-	-1.7	-	-					
Other expense	20.8	13.4	-7.4	-35.6%	43.3					
Loss on sales and disposal of property, plant and equipment	0.5	0.3	-0.3	-53.2%	1.2					
Impairment losses	8.3	6.6	-1.8	-21.2%	10.3					
Restructuring costs	11.3	-	-11.3	-	11.5					
Net foreign exchange losses	-	5.9	5.9	-	3.6					
Operating profit	103.2	132.6	29.4	28.5%	185.7	238.0	229.0	23.3%		
Ratio to Sales	17.4%	19.3%			14.9%	17.5%	16.5%			
Finance income	2.3	13.3	11.1	488.2%	7.1					
Gain on sales of available-for-sale financial assets	1.0	12.1	11.0	-	5.1					
Finance expense	2.8	0.6	-2.2	-79.6%	3.1					
Impairment losses for available-for-sale financial assets	2.6	0.1	-2.5	-96.0%	2.6					
Profit before tax	102.7	145.4	42.7	41.6%	189.7	239.0	242.0	27.6%		
Ratio to Sales	17.3%	21.2%			15.2%	17.5%	17.5%			
Income tax expense	32.7	42.5	9.8	30.0%	53.8					
Profit for the period	70.0	102.9	32.9	47.1%	135.9	170.0	172.0	26.6%		
Ratio to Sales	11.8%	15.0%			10.9%	12.5%	12.4%			
Comprehensive income	87.8	104.9	17.1	19.5%	169.5					

2. Consolidated Results (Core Basis)		billion yen				FY14 Full Year	Initial Forecasts		Revised Forecasts		Change from FY14	
		FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)		FY15 Full Year	FY15 Full Year	FY15 Full Year	Change (%)		
Sales		594.5	687.5	93.0	15.7%	1,247.3	1,362.0	1,384.0			11.0%	
Cost of sales		159.1	168.4	9.3	5.8%	333.2						
	Ratio to Sales	26.8%	24.5%			26.7%						
Gross profit		435.4	519.1	83.7	19.2%	914.1						
SG&A expenses		201.8	239.7	38.0	18.8%	452.5						
	Ratio to Sales	33.9%	34.9%			36.3%						
Advertising and Sales Promotion		55.0	83.3	28.3	51.4%	138.5						
Personnel expenses		85.3	91.3	6.0	7.0%	178.1						
Other		61.4	65.1	3.7	6.0%	136.0						
R&D expenses		97.0	112.0	15.0	15.5%	206.6	229.0	238.0			15.2%	
	Ratio to Sales	16.3%	16.3%			16.6%	16.8%	17.2%				
Amortisation of intangible assets		17.9	21.9	4.0	22.1%	38.7						
Share of profits/losses of associates and joint ventures		0.5	-0.3	-0.8	-	0.2						
Operating profit		119.2	145.2	26.0	21.8%	216.5	238.0	244.0			12.7%	
	Ratio to Sales	20.0%	21.1%			17.4%	17.5%	17.6%				
Finance income		1.2	1.3	0.1	5.6%	1.9						
Finance expense		0.2	0.3	0.1	81.4%	0.4						
Profit before Tax		120.2	146.2	25.9	21.6%	218.1						
	Ratio to Sales	20.2%	21.3%			17.5%						
Income tax expense		39.2	42.2	3.0	7.8%	64.8						
Profit for the period		81.1	103.9	22.9	28.2%	153.2	170.0	175.0			14.2%	
	Ratio to Sales	13.6%	15.1%			12.3%	12.5%	12.6%				

3. Exchange Rate

	yen				FY14 Full Year	Initial Forecasts		Revised Forecasts	
	FY14 APR. - SEP.Ave.	FY15 APR. - SEP.Ave.	FY14 End	FY15 2Q End		FY15 Full Year	FY15 Full Year		
USD/Yen	103	122	120	120	110	120	121		
EUR/Yen	139	135	130	135	139	125	133		

* Exchange rate fluctuations had positive impact by 36.0 billion yen on sales and positive impact by 9.6 billion yen on Core operating profit in Q2/FY2015

4. Reconciliation of Full Basis to Core Basis

Billion yen

Account item	FY14 APR. - SEP.			FY15 APR. - SEP.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	594.5	-	594.5	687.5	-	687.5
Cost of sales	159.1	-	159.1	168.4	-	168.4
Gross profit	435.4	-	435.4	519.1	-	519.1
SG&A expenses	201.8	-	201.8	239.7	-	239.7
R&D expenses	97.0	-	97.0	112.0	-	112.0
Amortisation of intangible assets	17.9	-	17.9	21.9	-	21.9
Share of profits/losses of associates and joint ventures	0.5	-	0.5	-0.3	-	-0.3
Other income *1	4.9	-4.9	-	0.9	-0.9	-
Other expense *1	20.8	-20.8	-	13.4	-13.4	-
Operating profit	103.2	16.0	119.2	132.6	12.5	145.2
Finance income *2	2.3	-1.0	1.2	13.3	-12.1	1.3
Finance expense *2	2.8	-2.6	0.2	0.6	-0.3	0.3
Profit before tax	102.7	17.6	120.2	145.4	0.7	146.2
Income tax expense	32.7	6.5	39.2	42.5	-0.3	42.2
Profit for the period	70.0	11.1	81.1	102.9	1.0	103.9

*1. "Other income" and "Other expense" are excluded from Core results.

"Other income" and "Other expense" include gain/loss on sale and disposal of property, plant and equipment, impairment losses for other intangible assets, loss on the restructuring, and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale ("AFS") and impairment losses of AFS included in "Finance income" and "Finance expense" are excluded from Core results as non-core items.

5. Segment Information by Region

		billion yen				Change from FY14			
		FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change (%)
Sales		594.5	687.5	93.0	15.7%	1,247.3	1,362.0	1,384.0	11.0%
Japan		237.2	247.1	9.9	4.2%	498.7	521.7	504.4	1.2%
Ratio to Sales		39.9%	35.9%			40.0%	38.3%	36.4%	
Americas		168.0	232.9	64.9	38.6%	361.0	439.8	452.1	25.2%
Ratio to Sales		28.3%	33.9%			28.9%	32.3%	32.7%	
EMEA		156.5	162.3	5.8	3.7%	313.3	309.4	335.0	6.9%
Ratio to Sales		26.3%	23.6%			25.1%	22.7%	24.2%	
Asia and Oceania		32.7	45.2	12.5	38.3%	74.2	91.1	92.5	24.6%
Ratio to Sales		5.5%	6.6%			5.9%	6.7%	6.7%	

- Calculated according to locations of sellers.

- EMEA: Europe, Middle East and Africa

6. Per Share Information

	FY14 APR. - SEP.	FY15 APR. - SEP.	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year
The number of shares issued (thousand)	2,259,823	2,221,823	2,259,823		
Treasury Shares (thousand)	51,959	64,020	66,681		
The number of shares issued after deducting Treasury Shares (thousand)	2,207,864	2,157,802	2,193,141		
Earnings per share (Yen)	31.61	47.30	61.50	78.08 *	79.37
Earnings per share (Yen) core base	36.61	47.76	69.37	78.08 *	80.76
Dividend per share (Yen)	14	16	30	32	32

* The initial forecasts for "Earnings per share (Yen) " and "Earnings per share (Yen) core base " reflect acquisitions of own shares carried out from May 28 to July 10, 2015.

7. Addition to Property, Plant and Equipment

Depreciation/Amortisation		billion yen				Change from FY14			
		FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change (%)
Addition to Property, Plant and Equipment									
Consolidated		10.7	18.4	7.7	71.9%	30.6	35.0	35.0	14.4%
Depreciation(PP&E)									
Consolidated		10.8	10.2	-0.6	-5.4%	21.3	22.5	22.5	5.5%
Amortisation(Intangible Assets) *									
Consolidated		20.6	24.8	4.2	20.6%	44.2	53.0	50.0	13.2%

* Amortisation(Intangible Assets): Including amortisation of software, etc.

8. Sales of major products

1) Sales of global products

	billion yen				FY14 Full Year	Change from FY14		
	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)		Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change (%)
XTANDI	54.6	122.3	67.7	124.0%	137.2	229.4	253.3	84.6%
US	33.5	74.5	41.0	122.3%	85.7	141.6	147.6	72.2%
ex-US	21.1	47.9	26.7	126.6%	51.5	87.8	105.8	105.3%
Japan	5.6	13.1	7.5	132.5%	14.9	23.0	28.0	88.4%
Americas (ex-US)	0.9	2.3	1.3	137.7%	2.6	4.2	4.3	65.2%
EMEA	14.5	31.5	17.1	118.0%	33.4	58.8	71.1	112.8%
Asia and Oceania	0.1	1.0	0.9	994.9%	0.6	1.9	2.3	280.8%
Eligard	9.5	8.8	-0.6	-6.5%	19.0	18.1	18.2	-4.3%
EMEA	9.4	8.7	-0.7	-7.4%	18.9	17.9	18.0	-5.1%
Asia and Oceania	0.0	0.1	0.1	552.1%	0.1	0.2	0.2	219.8%
Vesicare	66.6	69.7	3.1	4.7%	135.2	132.9	133.4	-1.3%
Japan	11.8	13.3	1.5	12.7%	25.6	26.4	27.0	5.5%
Americas	30.6	33.3	2.8	9.0%	61.4	63.8	62.4	1.5%
EMEA	21.4	20.3	-1.1	-5.0%	42.3	36.0	38.2	-9.7%
Asia and Oceania	2.4	2.6	0.2	9.3%	5.3	6.3	5.6	5.1%
Betanis/Myrbetriq/Betmiga	22.3	38.1	15.7	70.5%	53.1	79.3	81.9	54.0%
Japan	6.1	9.7	3.6	59.7%	14.8	23.0	22.1	49.2%
Americas	12.2	21.4	9.3	76.2%	27.9	40.8	44.3	59.0%
EMEA	4.0	6.6	2.6	65.1%	10.3	14.8	14.6	41.7%
Asia and Oceania	0.1	0.3	0.2	414.4%	0.2	0.6	0.9	420.0%
Harnal	27.4	27.1	-0.3	-1.1%	56.0	53.7	56.0	0.0%
Sales by Astellas	25.6	25.7	0.1	0.4%	51.9	49.5	52.0	0.1%
Japan	7.8	6.7	-1.1	-14.4%	15.0	12.9	12.8	-14.4%
EMEA	9.1	8.0	-1.1	-12.0%	18.0	14.7	16.7	-7.0%
Asia and Oceania	8.4	10.6	2.2	25.9%	18.3	21.2	21.8	19.3%
Bulk and Royalties	1.9	1.5	-0.4	-21.2%	4.1	4.2	4.0	-2.0%
Prograf	95.2	104.6	9.4	9.9%	194.7	192.6	202.5	4.0%
Sales by Astellas	93.4	103.1	9.7	10.3%	190.9	190.1	199.8	4.7%
Japan (Including Gracceptor)	23.7	25.4	1.7	7.3%	48.1	49.9	50.7	5.3%
Americas	16.9	18.1	1.2	7.0%	33.0	32.4	33.3	0.7%
EMEA	38.4	40.1	1.8	4.6%	77.7	68.6	77.3	-0.5%
Advagraf	14.0	15.8	1.9	13.3%	28.7			
Asia and Oceania	14.4	19.4	5.0	34.6%	32.0	39.2	38.5	20.6%
Exports to third parties	1.8	1.5	-0.2	-14.1%	3.8	2.5	2.7	-30.6%
Funguard/Mycamine	18.5	21.1	2.6	14.1%	38.8	40.6	42.4	9.3%
Japan	5.7	6.1	0.3	5.8%	11.8	12.2	12.1	3.0%
Americas	5.7	6.7	1.0	18.2%	12.4	12.3	12.9	4.7%
EMEA	5.1	5.6	0.5	10.1%	10.2	9.9	11.7	14.1%
Asia and Oceania	2.0	2.7	0.7	36.3%	4.4	6.2	5.6	28.2%
Protopic	12.1	9.2	-2.8	-23.6%	21.7	13.7	14.9	-31.2%
Americas	6.5	3.3	-3.2	-49.5%	10.3	2.6	2.9	-71.7%
EMEA	3.9	3.3	-0.6	-15.0%	7.8	6.6	7.0	-10.3%
Asia and Oceania	1.6	2.5	0.9	55.8%	3.4	4.3	4.8	39.6%

- Sales of products in Japan are shown in a gross sales basis.

- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

	billion yen				FY14 Full Year	Change from FY14		
	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)		Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change (%)
<Global products>								
XTANDI	5.6	13.1	7.5	132.5%	14.9	23.0	28.0	88.4%
Vesicare	11.8	13.3	1.5	12.7%	25.6	26.4	27.0	5.5%
Betanis	6.1	9.7	3.6	59.7%	14.8	23.0	22.1	49.2%
Harnal	7.8	6.7	-1.1	-14.4%	15.0	12.9	12.8	-14.4%
Prograf (Including Gracceptor)	23.7	25.4	1.7	7.3%	48.1	49.9	50.7	5.3%
Funguard	5.7	6.1	0.3	5.8%	11.8	12.2	12.1	3.0%
<Local products in Japan>								
Micardis [Family]	47.1	48.5	1.4	3.0%	95.7	105.2	98.5	2.9%
Micombi	5.4	5.1	-0.3	-5.2%	10.7			
Micamlo	11.4	12.7	1.3	11.3%	23.8			
Celecox	19.6	23.4	3.8	19.4%	41.8	49.6	46.9	12.4%
Symbicort	14.5	17.5	3.0	21.0%	33.0	38.1	37.0	12.2%
Bonoteo	6.1	7.1	1.0	16.8%	13.0	14.4	14.5	11.5%
Geninax	4.3	4.8	0.4	10.0%	10.4	10.4	10.6	2.7%
Vaccines	12.6	14.0	1.4	10.9%	38.8	42.4	40.0	3.1%
Argamate	2.9	3.1	0.1	4.7%	5.9	6.4	6.2	3.6%
Kiklin	0.7	0.8	0.1	12.1%	1.5	2.2	1.7	12.1%
Gonax	1.6	1.9	0.3	18.3%	3.4	4.2	4.0	17.7%
Cimzia	2.4	3.2	0.8	34.8%	5.0	7.5	6.7	34.0%
Suglat	2.6	3.5	0.9	34.7%	4.1	11.0	8.3	102.6%
Lipitor*	19.3	16.3	-3.1	-15.9%	36.7	30.6	30.5	-17.0%
Myslee	9.8	9.2	-0.6	-6.1%	19.4	18.1	17.6	-9.1%
Gaster	9.5	7.7	-1.8	-18.6%	18.0	15.1	14.8	-17.8%
Seroquel	6.6	5.7	-0.9	-14.3%	12.6	10.6	10.7	-15.1%
Total Rx Sales In Japanese market	229.5	240.0	10.5	4.6%	481.7	507.0	489.8	1.7%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015. Sales in FY2014 exclude sales of Caduet.

3) Sales of products in Americas and EMEA

	billion yen				FY14 Full Year	Change from FY14		
	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)		Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change (%)
Scan* (Americas)	32.2	40.6	8.4	26.0%	66.3	74.3	77.8	17.3%
Lexiscan	32.1	40.5	8.4	26.3%	65.9			
AmBisome (Americas)	4.2	5.5	1.3	32.3%	9.0	9.7	10.4	15.7%
Tarceva	24.7	25.5	0.8	3.3%	48.9			
(US)	17.2	18.6	1.4	8.0%	33.5			
(ex-US)	7.5	6.9	-0.6	-7.6%	15.3			
Qutenza (EMEA)	0.9	1.0	0.1	16.0%	1.9			
DIFICLIR (EMEA)	1.0	1.3	0.3	35.9%	2.0			

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4)Sales in Americas and EMEA(Local currency)

Americas	Unit:M\$				FY14 Full Year	Change from FY14		
	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)		Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change (%)
Net Sales	1,631	1,912	281	17.3%	3,284	3,665	3,739	13.9%
XTANDI	334	630	296	88.4%	803	1,215	1,256	56.4%
US	325	611	286	88.0%	779	1,180	1,220	56.6%
Americas (ex-US)	9	19	9	101.1%	24	35	36	50.2%
Tarceva	240	210	-30	-12.6%	444			
US	167	153	-14	-8.7%	305			
ex-US	73	57	-16	-21.8%	139			
VESicare	296	273	-23	-7.8%	559	532	516	-7.7%
Myrbetriq	118	176	58	49.1%	254	340	367	44.6%
Prograf	164	149	-16	-9.5%	301	270	275	-8.4%
Scan*	313	333	21	6.6%	603	619	643	6.7%
Lexiscan	311	332	21	6.8%	599			
MYCAMINE	55	55	-0	-0.0%	112	102	107	-4.8%
AmBisome	40	45	5	11.9%	82	81	86	5.2%
CRESEMBA	-	7	7	-	-			
Protopic	63	27	-36	-57.3%	94	21	24	-74.2%

* Adenoscan + Lexiscan

EMEA	Unit:ME				FY14 Full Year	Change from FY14		
	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)		Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change (%)
Net Sales	1,127	1,201	75	6.6%	2,258	2,475	2,528	12.0%
XTANDI	104	233	129	124.2%	241	470	537	122.8%
Eligard	68	65	-3	-4.7%	136	143	136	-0.6%
Vesicare	154	150	-4	-2.3%	305	288	288	-5.4%
BETMIGA	29	49	20	69.8%	74	119	110	48.3%
Harnal (Omnice)	79	70	-9	-11.1%	159	151	157	-1.7%
Sales by Astellas	66	59	-6	-9.5%	130	118	126	-2.7%
Capsule	33	29	-4	-11.9%	63	60	64	0.8%
OCAS	33	31	-2	-7.2%	66	58	62	-6.0%
Bulk and Royalties	13	11	-3	-18.9%	30	33	30	2.6%
Prograf	289	308	19	6.7%	588	569	603	2.7%
Sales by Astellas	276	297	21	7.6%	560	549	583	4.1%
Advagraf	100	117	17	16.6%	207			
Exports to third parties	13	11	-1	-11.6%	28	20	20	-27.0%
MYCAMINE	37	42	5	13.2%	74	80	88	19.4%
Protopic	28	24	-3	-12.6%	56	53	53	-6.1%
Qutenza	6	7	1	19.3%	13			
DIFICLIR	7	10	3	39.8%	14			

- EMEA: Europe, Middle East and Africa

9.Consolidated statements of financial position

Billion yen

	31-Mar-15	30-Sep-15	Change
	Amount	Amount	
Assets	1,793.6	1,770.7	-22.9
Non-current assets	827.6	817.1	-10.5
Property, plant and equipment	202.9	203.7	0.8
Goodwill	136.3	136.1	-0.2
Other intangible assets	295.8	285.7	-10.2
Trade and other receivables	15.6	21.0	5.4
Investments in associates and joint ventures	2.0	3.1	1.1
Deferred tax assets	51.2	60.1	8.9
Other financial assets	110.1	91.6	-18.4
Other non-current assets	13.7	15.8	2.2
Current assets	966.0	953.6	-12.4
Inventories	156.9	159.1	2.2
Trade and other receivables	332.9	351.2	18.3
Income tax receivable	6.9	8.9	2.0
Other financial assets	59.9	28.8	-31.1
Other current assets	12.7	17.4	4.6
Cash and cash equivalents	396.4	388.1	-8.3
Assets held for sale	0.1	-	-0.1

Billion yen

	31-Mar-15	30-Sep-15	Change
	Amount	Amount	
Equity and Liabilities	1,793.6	1,770.7	-22.9
Equity	1,317.9	1,323.1	5.2
Equity attributable to owners of the parent	1,317.9	1,323.1	5.2
Share capital	103.0	103.0	-
Capital surplus	176.8	176.8	0.0
Treasury shares	-87.0	-102.0	-15.0
Retained earnings	905.1	925.2	20.1
Other components of equity	220.0	220.0	-0.0
Liabilities	475.7	447.6	-28.1
Non-current liabilities	54.8	52.4	-2.4
Trade and other payables	0.1	1.8	1.7
Deferred tax liabilities	0.0	-	-0.0
Retirement benefit liabilities	30.1	29.5	-0.6
Provisions	4.8	3.4	-1.4
Other financial liabilities	0.6	0.8	0.2
Other non-current liabilities	19.1	16.9	-2.2
Current liabilities	420.9	395.2	-25.7
Trade and other payables	226.6	202.0	-24.6
Income tax payable	14.1	18.5	4.3
Provisions	85.4	89.2	3.8
Other financial liabilities	1.3	1.1	-0.2
Other current liabilities	93.4	84.4	-9.0

10. Employee

Number of employees

	FY14 2Q End	FY15 2Q End
Total	17,536	17,352
Japan	7,698	7,300
Americas	2,939	2,957
EMEA	4,681	4,727
Asia and Oceania	2,218	2,368
Total Medical Representatives	6,540	6,220

- EMEA: Europe, Middle East and Africa

FY14 FY End
17,113
7,241
2,975
4,628
2,269
6,530

11. Shareholders

	FY14 2Q End	FY15 2Q End
Banks	30.5%	30.5%
Securities	3.6%	3.6%
Other companies	3.4%	3.4%
Foreign companies	52.7%	51.4%
Individuals and others	7.5%	8.2%
Treasury Stock	2.3%	2.9%

[Three months ended September 30, 2015]

1. Consolidated Results (Full Basis)

bilion yen

	FY15			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Sales	343.7	16.4%	343.8	14.9%
Cost of sales	90.1	18.6%	78.3	-5.8%
Ratio to Sales	26.2%		22.8%	
Gross profit	253.6	15.7%	265.5	22.8%
SG&A expenses	118.7	22.4%	121.1	15.5%
Ratio to Sales	34.5%		35.2%	
Advertising and Sales Promotion	41.6	47.7%	41.7	55.3%
Personnel expenses	45.1	6.3%	46.2	7.7%
Other	32.0	21.4%	33.2	-5.5%
R&D expenses	56.0	17.5%	56.1	13.5%
Ratio to Sales	16.3%		16.3%	
Amortisation of intangible assets	10.9	22.8%	11.0	21.5%
Share of profits/losses of associates and joint ventures	-0.2	-	-0.0	-
Other income	1.3	-53.2%	0.3	-91.0%
Gain on sales of property, plant and equipment	0.1	799.6%	0.1	-92.5%
Net foreign exchange gains	0.6	-74.3%	-	-
Other expense	7.2	-60.4%	6.9	98.4%
Loss on sales and disposal of property, plant and equipment	0.1	-54.9%	0.2	-52.3%
Impairment losses	6.6	-18.7%	-	-
Restructuring costs	-	-	-	-
Net foreign exchange losses	-	-	6.5	794.3%
Operating profit	61.9	22.4%	70.7	34.4%
Ratio to Sales	18.0%		20.6%	
Finance income	6.0	230.4%	7.3	-
Gain on sales of available-for-sale financial assets	5.5	540.2%	6.6	-
Finance expense	0.3	-86.9%	0.3	-56.6%
Impairment losses for available-for-sale financial assets	0.0	-98.5%	0.1	-87.8%
Profit before tax	67.7	34.6%	77.8	48.4%
Ratio to Sales	19.7%		22.6%	
Income tax expense	23.0	59.8%	19.4	6.4%
Profit for the period	44.6	24.4%	58.3	70.9%
Ratio to Sales	13.0%		17.0%	
Comprehensive income	71.8	219.0%	33.0	-49.4%

2. Consolidated Results (Core Basis)

billion yen

		FY15			
		APR.-JUN.	Change	JUL.-SEP.	Change
		(Quarterly)	(%)	(Quarterly)	(%)
Sales		343.7	16.4%	343.8	14.9%
Cost of sales		90.1	18.6%	78.3	-5.8%
	Ratio to Sales	26.2%		22.8%	
Gross profit		253.6	15.7%	265.5	22.8%
SG&A expenses		118.7	22.4%	121.1	15.5%
	Ratio to Sales	34.5%		35.2%	
Advertising and Sales Promotion		41.6	47.7%	41.7	55.3%
Personnel expenses		45.1	6.3%	46.2	7.7%
Other		32.0	21.4%	33.2	-5.5%
R&D expenses		56.0	17.5%	56.1	13.5%
	Ratio to Sales	16.3%		16.3%	
Amortisation of intangible assets		10.9	22.8%	11.0	21.5%
Share of profits/losses of associates and joint ventures		-0.2	-	-0.0	-
Operating profit		67.8	2.8%	77.3	45.4%
	Ratio to Sales	19.7%		22.5%	
Finance income		0.6	-43.2%	0.7	188.6%
Finance expense		0.1	-20.5%	0.2	257.6%
Profit before Tax		68.3	2.2%	77.9	45.8%
	Ratio to Sales	19.9%		22.6%	
Income tax expense		23.3	13.8%	19.0	1.1%
Profit for the period		45.0	-3.0%	58.9	70.0%
	Ratio to Sales	13.1%		17.1%	

3. Segment Information by Region

bilion yen

		FY15			
		APR.-JUN.	Change	JUL.-SEP.	Change
		(Quarterly)	(%)	(Quarterly)	(%)
Sales		343.7	16.4%	343.8	14.9%
Japan		125.6	11.3%	121.5	-2.3%
	Ratio to Sales	36.6%		35.3%	
Americas		114.8	36.9%	118.1	40.3%
	Ratio to Sales	33.4%		34.4%	
EMEA		81.7	-0.8%	80.5	8.7%
	Ratio to Sales	23.8%		23.4%	
Asia and Oceania		21.5	34.0%	23.7	42.4%
	Ratio to Sales	6.3%		6.9%	

- Calculated according to locations of sellers.

- EMEA: Europe, Middle East and Africa

4. Addition to Property, Plant and Equipment Depreciation/Amortisation

bilion yen

		FY15			
		APR.-JUN.	Change	JUL.-SEP.	Change
		(Quarterly)	(%)	(Quarterly)	(%)
Addition to Property, Plant and Equipment					
	Consolidated	12.6	273.1%	5.8	-20.9%
Depreciation(PP&E)					
	Consolidated	5.0	-4.5%	5.2	-6.2%
Amortisation(Intangible Assets) *					
	Consolidated	12.4	21.1%	12.5	20.0%

* Amortisation(Intangible Assets): Including amortisation of software, etc.

5. Sales of major products

1) Sales of global products

bilion yen

	FY15			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	59.1	152.8%	63.3	102.4%
US	36.2	146.7%	38.3	103.2%
ex-US	22.8	163.2%	25.0	101.1%
Japan	6.8	346.5%	6.3	53.3%
Americas (ex-US)	1.0	151.6%	1.2	127.0%
EMEA	14.6	117.3%	16.9	118.6%
Asia and Oceania	0.4	-	0.6	937.5%
Eligard	4.4	-12.3%	4.4	0.3%
EMEA	4.4	-12.9%	4.3	-0.9%
Asia and Oceania	0.0	349.7%	0.1	819.7%
Vesicare	35.4	7.1%	34.3	2.3%
Japan	6.8	29.6%	6.5	-0.9%
Americas	17.1	9.9%	16.2	8.1%
EMEA	10.2	-7.2%	10.1	-2.7%
Asia and Oceania	1.2	7.6%	1.4	10.8%
Betanis/Myrbetriq/BETMIGA	18.1	69.1%	20.0	71.7%
Japan	4.9	81.0%	4.9	42.9%
Americas	9.8	59.7%	11.6	93.2%
EMEA	3.3	79.7%	3.3	52.7%
Asia and Oceania	0.1	447.7%	0.2	396.9%
Harnal	14.2	3.4%	12.9	-5.6%
Sales by Astellas	13.3	6.2%	12.4	-5.2%
Japan	3.4	-11.6%	3.3	-17.1%
EMEA	4.7	3.7%	3.3	-27.6%
Asia and Oceania	5.0	25.5%	5.6	26.3%
Bulk and Royalties	0.9	-25.4%	0.5	-13.1%
Prograf	50.4	7.1%	54.2	12.6%
Sales by Astellas	49.9	8.0%	53.2	12.6%
Japan (Including Gracceptor)	12.7	11.0%	12.7	3.7%
Americas	8.4	-4.5%	9.7	19.4%
EMEA	19.6	5.2%	20.5	4.0%
Advagraf	7.5	13.8%	8.3	12.9%
Asia and Oceania	9.2	25.7%	10.3	43.7%
Exports to third parties	0.5	-41.3%	1.0	13.1%
Funguard/MYCAMINE	10.3	16.3%	10.8	12.0%
Japan	2.9	16.5%	3.1	-2.5%
Americas	3.3	15.5%	3.4	20.9%
EMEA	2.8	6.5%	2.8	14.0%
Asia and Oceania	1.3	49.2%	1.4	26.5%
Protopic	4.7	-22.5%	4.5	-24.6%
Americas	1.5	-51.7%	1.8	-47.5%
EMEA	1.8	-13.4%	1.5	-17.0%
Asia and Oceania	1.3	66.7%	1.3	46.1%

- Sales of products in Japan are shown in a gross sales basis.

- EMEA: Europe, Middle East and Africa

2)Sales of products in Japan

bilion yen

<Global products>	FY15			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	6.8	346.5%	6.3	53.3%
Vesicare	6.8	29.6%	6.5	-0.9%
Betanis	4.9	81.0%	4.9	42.9%
Harnal	3.4	-11.6%	3.3	-17.1%
Prograf (Including Graceptor)	12.7	11.0%	12.7	3.7%
Funguard	2.9	16.5%	3.1	-2.5%
<Local products in Japan>				
Micardis [Family]	24.8	6.3%	23.7	-0.3%
Micombi	2.7	-3.0%	2.5	-7.5%
Micamlo	6.5	14.5%	6.2	8.1%
Celecox	11.8	41.4%	11.6	3.0%
Symbicort	9.0	44.2%	8.5	3.5%
Bonoteo	3.7	39.8%	3.4	-0.9%
Geninax	2.8	20.9%	2.0	-2.5%
Vaccines	6.6	24.6%	7.4	1.1%
Argamate	1.5	6.5%	1.5	2.9%
Kiklin	0.4	23.2%	0.4	3.0%
Gonax	0.9	26.1%	1.0	11.6%
Cimzia	1.6	40.1%	1.6	29.9%
Suglat	2.0	-18.2%	1.4	-
Lipitor*	8.3	-13.1%	7.9	-18.6%
Myslee	4.7	-3.6%	4.6	-8.5%
Gaster	3.9	-17.4%	3.8	-19.8%
Seroquel	3.0	-13.4%	2.7	-15.3%
Total Rx Sales In Japanese market	122.2	12.1%	117.8	-2.3%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015.

3)Sales of products in Americas and EMEA

bilion yen

	FY15			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Scan* (Americas)	20.8	25.1%	19.8	27.1%
Lexiscan	20.8	26.2%	19.7	26.4%
AmBisome (Americas)	2.8	47.7%	2.7	19.5%
Tarceva	13.1	-3.2%	12.4	11.1%
(US)	9.7	0.5%	8.9	17.4%
(ex-US)	3.4	-12.3%	3.5	-2.4%
Qutenza (EMEA)	0.5	16.3%	0.5	15.6%
DIFICLIR (EMEA)	0.6	34.7%	0.7	37.1%

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4)Sales in Americas and EMEA(Local currency)

Unit:M\$

	FY15			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Americas				
Net Sales	946	15.2%	966	19.3%
XTANDI	307	107.8%	323	73.1%
US	298	107.6%	313	72.5%
Americas (ex-US)	9	111.8%	10	92.7%
Tarceva	108	-18.5%	101	-5.4%
US	80	-15.4%	73	0.0%
ex-US	28	-26.1%	28	-16.9%
VESicare	141	-7.5%	133	-8.0%
Myrbetriq	81	34.4%	95	64.4%
Prograf	69	-19.6%	80	1.6%
Scan*	171	5.3%	162	8.1%
Lexiscan	171	6.2%	161	7.5%
MYCAMINE	27	-2.8%	28	2.8%
AmBisome	23	24.3%	22	1.4%
CRESEMBA	2	-	5	-
Protopic	12	-59.4%	14	-55.4%

* Adenoscan + Lexiscan

Unit:M€

	FY15			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
EMEA				
Net Sales	609	3.5%	592	10.0%
XTANDI	109	126.9%	125	121.9%
Eligard	33	-9.1%	32	0.3%
Vesicare	76	-3.1%	75	-1.4%
BETMIGA	25	87.7%	25	54.9%
Harnal (Omnice)	42	1.8%	28	-25.2%
Sales by Astellas	35	8.2%	24	-26.9%
Capsule	18	14.3%	11	-37.0%
OCAS	17	2.4%	14	-16.7%
Bulk and Royalties	7	-22.1%	4	-13.0%
Prograf	150	7.6%	158	5.9%
Sales by Astellas	146	9.8%	151	5.5%
Advagraf	56	18.8%	61	14.6%
Exports to third parties	4	-38.8%	7	15.0%
MYCAMINE	21	11.2%	20	15.4%
Protopic	14	-9.5%	11	-16.2%
Qutenza	4	21.5%	3	16.9%
DIFICLIR	5	40.7%	5	39.0%

- EMEA: Europe, Middle East and Africa